Your browser doesn't support javascript.
loading
Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer.
Tanishima, Yuichiro; Nishikawa, Katsunori; Arakawa, Yasuhiro; Matsumoto, Akira; Yuda, Masami; Tanaka, Yujiro; Mitsumori, Norio; Yanaga, Katsuhiko.
Afiliação
  • Tanishima Y; Division of Gastroenterological Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan tanishima@jikei.ac.jp.
  • Nishikawa K; Division of Gastroenterological Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Arakawa Y; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Matsumoto A; Division of Gastroenterological Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Yuda M; Division of Gastroenterological Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Tanaka Y; Division of Gastroenterological Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Mitsumori N; Division of Gastroenterological Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Yanaga K; Division of Gastroenterological Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Anticancer Res ; 40(10): 5829-5835, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32988912
ABSTRACT

BACKGROUND:

Preoperative chemotherapy with surgery is the most effective treatment modality in Japan for advanced oesophageal squamous cell carcinoma (OSCC). We evaluated the long-term outcomes associated with preoperative docetaxel/cisplatin/5-fluorouracil (DCF) administration followed by oesophagectomy in OSCC. PATIENTS AND

METHODS:

Overall, 76 consecutive patients with cStage IB-IIIC OSCC were enrolled. After two cycles of preoperative DCF, oesophagectomy was performed. Survival monitoring was performed and relevant risk factors were analysed.

RESULTS:

The median follow-up period was 88.3 months. The 5-year overall and recurrence-free survival rates were 51% and 43%, respectively. In the multivariable analysis, cT3 stage [hazard ratio (HR)=1.81, 95% confidence interval (CI)=1.08-6.16], incomplete chemotherapy (HR=2.35, 95% CI=1.37-4.02), poor clinical response (HR=1.82, 95% CI=1.01-3.29), and postoperative complications (HR=2.11, 95% CI=1.14-3.90) were independent predictors of poorer overall survival.

CONCLUSION:

The 5-year outcomes of preoperative DCF with oesophagectomy were favourable. Our findings can aid in the formulation of strategies aimed at improving prognosis in OSCC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prognóstico / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Metástase Linfática Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Anticancer Res Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prognóstico / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Metástase Linfática Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Anticancer Res Ano de publicação: 2020 Tipo de documento: Article